ROCHESTER, Minn. / Sep 14, 2023 / Business Wire / Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
The Strategic Collaboration for Innovation in Medical Imaging and Theranostics comprises Mayo Clinic and GE HealthCare scientists, technology developers, clinicians and other healthcare providers. The collaboration seeks to better equip clinicians with technology to precisely diagnose and treat medical conditions and personalize the patient experience at each step of their care journey through the clinical translation of novel technologies and approaches to medical imaging and theranostics.
“We are at a critical time in healthcare – technology is rapidly evolving, and we have a responsibility to drive healthcare capabilities through clinical translation and adoption of advanced technologies,” says Matthew Callstrom, M.D., Ph.D., chair of Radiology at Mayo Clinic in Rochester, Minnesota. “This collaboration brings our research and clinical teams’ expertise and feedback closer to product development and commercialization of innovation, ultimately accelerating the rate of translation of our research to patient care and offering greater opportunity for global impact.”
Building upon a long history of research collaborations between the two organizations, the alliance will deepen the collaborative efforts by focusing on four core areas:
“Mayo Clinic is globally acknowledged to be among the best in healthcare and care innovation. By collaborating with their scientists, inventors and healthcare providers, we will accelerate innovation and increase the clinical impact of our technologies beyond what either of our organizations could achieve independently,” says Jan Makela, president and CEO of Imaging, GE HealthCare.
The multi-focal collaboration brings together clinical research, product development, application of new clinical uses and techniques, and increased access for patients. It features close alignment between research teams and the medical departments that depend on radiological data, spanning multiple radiological disciplines, cardiology, oncology, radiation oncology, vascular, neurology, nuclear medicine and urology. Collaboration activities and research will take place at Mayo Clinic’s campus in Rochester, Minnesota.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
Last Trade: | US$77.09 |
Daily Change: | -2.16 -2.73 |
Daily Volume: | 3,055,620 |
Market Cap: | US$35.220B |
December 05, 2024 December 03, 2024 December 01, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB